Doctors are noticing a trend among their colleagues: they seem to be getting full before finishing dinner, likely thanks to GLP-1 drugs like Ozempic. Medical professionals who use these popular weight loss drugs, which replicate the stomach's feeling of fullness, have begun noticing each other. While there aren't any surveys tracking how many physicians take these drugs or what doses they're on, several doctors have openly shared their experiences.
Doctors have begun noticing a trend among their colleagues: they seem to be getting full before finishing dinner, likely thanks to GLP-1 drugs like Ozempic sweeping the medical profession ., medical profession als who use the popular weight loss drugs — which replicate the stomach's feeling of fullness — have begun sniffing each other out.
University of North Carolina diabetes specialist John Buse said he's shed 25 percent of his body weight, which "totally changed life" after years of struggling with his weight. Since starting on Wegovy, he's noticed that others in his field have lost a lot of weight — though he never asks people outright.
"Yes, you can definitely tell," the cardiologist said. "And when you go to dinners, you can definitely see. We eat, like, an eighth of our meal. I know what’s going on here.
GLP-1 Drugs Ozempic Weight Loss Medical Profession Health Trends
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
GLP-1 Drugs: A Weight Loss Solution or Overused Remedy?With rising obesity rates, GLP-1 drugs like Ozempic and Wegovy have gained popularity for weight loss. While effective, concerns remain about potential long-term health risks and overuse. This article explores the benefits and drawbacks of these drugs compared to traditional lifestyle changes.
Read more »
Large Study Finds No Increased Risk of Thyroid Cancer with GLP-1 RA DrugsA major new study involving a large diabetic population indicates that the use of GLP-1 RA drugs does not significantly increase the risk of thyroid cancer, although the study's relatively short follow-up period is noted.
Read more »
GLP-1 Agonist Drugs Offer More Benefits Than Risks for Approved Uses, Study FindsA comprehensive analysis of GLP-1 agonist drugs, used to treat type 2 diabetes and obesity, has revealed that they offer more benefits than risks for their approved uses. The study, which examined the health records of over 200,000 people with diabetes, found that GLP-1 agonists reduced the risk of various conditions, including heart attacks, dementia, and substance use disorders. However, the study also identified some potential downsides, such as an increased risk of kidney stones and pancreatitis.
Read more »
The Unexpected Side Effects of GLP-1 Drugs: A Discovery StudyDr. F. Perry Wilson discusses a groundbreaking study examining the wide-ranging effects of GLP-1 receptor agonists, commonly used for weight loss and diabetes management. The study, conducted using the vast dataset of the US Department of Veterans Affairs, employed a novel 'discovery' approach to identify both beneficial and potentially harmful outcomes associated with these drugs. This approach reveals intriguing insights beyond their established effects on weight and blood sugar, prompting further exploration into the multifaceted nature of GLP-1 drugs.
Read more »
Ozempic and GLP-1 Drugs: A Spectrum of Benefits and RisksA new study reveals the wide-ranging effects of Ozempic and other GLP-1 drugs, highlighting both their potential to improve health and the associated risks.
Read more »
GLP-1 Weight Loss Drugs Offer Health Benefits But Carry RisksA new study reveals that GLP-1 injectable weight loss drugs provide additional health benefits beyond weight management, but patients should be aware of potential side effects.
Read more »